Trump’s psychedelic policy shift exposes tensions between medical innovation, political control, and structural barriers to therapeutic access

Indigenous traditions worldwide have long used psychedelics as sacred medicines, governed by communal protocols, reciprocity, and ecological stewardship. The Western biomedical model’s rush to extract, isolate, and patent these substances mirrors historical patterns of colonial knowledge theft, such as the appropriation of quinine or rubber. Ceremonial practices like the Mazatec velada or the Shipibo icaros are not merely 'therapies' but living systems of cosmology, ethics, and relational accountability. The erasure of these frameworks in favor of FDA-approved drugs risks repeating the violence of the War on Drugs, which targeted indigenous and Black communities for their spiritual practices.

Psychedelics have been weaponized and suppressed in cycles: from CIA-funded MK-Ultra experiments in the 1950s–70s to Nixon’s War on Drugs, which criminalized substances like LSD and psilocybin while exempting alcohol and tobacco. The 1971 UN Convention on Psychotropic Substances codified this global prohibition, often at the behest of U.S. pressure, despite indigenous and Eastern traditions using these plants for millennia. The current 'renaissance' mirrors earlier booms (e.g., 1960s counterculture) that were abruptly halted by political backlash. This history reveals how psychedelic policy is less about science and more about controlling bodies, dissent, and alternative worldviews.

While the U.S. debates 'medicalization,' countries like Brazil and Portugal have decriminalized personal use of psychedelics, framing them as public health tools rather than criminalized substances. In the Amazon, ayahuasca is used in communal healing ceremonies where the plant’s spirit is considered a teacher, not a drug to be commodified. In contrast, Western models often extract these substances into standardized doses, stripping them of cultural context and reinforcing colonial patterns of knowledge appropriation. Indigenous leaders like those in the União do Vegetal have fought for decades to protect their ceremonial practices, yet their voices are conspicuously absent in U.S. policy discussions.

Psychedelics show promise in treating PTSD, depression, and addiction, with Phase 3 trials for MDMA (by MAPS) and psilocybin (by Compass Pathways) demonstrating significant efficacy. However, much of the research is funded by venture capital and pharmaceutical interests, prioritizing patentable compounds over holistic or community-based models. The FDA’s 'breakthrough therapy' designation has accelerated approval pathways, but this risks sidelining rigorous, long-term studies on dosage, set/setting, and integration. Additionally, the militarized origins of psychedelic research (e.g., CIA experiments) raise ethical questions about how these substances are studied and who benefits from their commercialization.

Psychedelics have long been intertwined with artistic and spiritual movements, from the Beat Generation’s experiments with peyote to the synesthetic visions of Alex Grey or the psychedelic rock of the 1960s. These substances have been tools for artists, mystics, and activists to challenge dominant paradigms, whether through Timothy Leary’s 'Turn on, tune in, drop out' or the ayahuasca-inspired art of Pablo Amaringo. Yet, the current biomedical framing risks reducing these experiences to mere 'treatments,' stripping them of their transformative, communal, and even revolutionary potential. The spiritual dimension—whether in indigenous ceremonies or modern psychedelic retreats—often emphasizes interconnectedness, a counter-narrative to capitalist individualism.

If current trends continue, psychedelic therapies may become a luxury commodity accessible only to the wealthy, mirroring the trajectory of other 'breakthrough' treatments like CAR-T cell therapy. Scenarios range from utopian (equitable access via public health systems) to dystopian (corporate monopolies controlling patents, with indigenous knowledge exploited without compensation). The integration of psychedelics into mainstream medicine could also lead to their co-optation by surveillance capitalism, where data from 'trips' is monetized or used for behavioral manipulation. Alternative models, such as community clinics or indigenous-led healing centers, offer more sustainable pathways but require structural support.

Marginalized communities—particularly Black, Indigenous, and LGBTQ+ individuals—have historically been both targeted by psychedelic prohibition and excluded from research participation. For example, Black Americans are less likely to be included in clinical trials for psychedelic-assisted therapy, despite bearing disproportionate burdens of trauma and mental health disparities. Indigenous leaders, who have preserved these traditions for centuries, are often sidelined in favor of Western scientists and corporations. Additionally, disabled and neurodivergent communities, who may benefit from psychedelic therapies, face barriers to access due to cost, insurance discrimination, and lack of culturally competent providers.